William Fallin
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 28.0% of the total. Reporting peaked in 2021 at $760 and has fallen 93.1% since, to $53 in 2025.
Across 140 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$587
- AstraZeneca$359
- Merck$201
- Novo Nordisk$200
- Lilly USA, LLC$116
- Takeda Pharmaceuticals U.S.A., Inc.$98
- plus $538 from 13 others
What the payments were for
- Food & beverage$2,099100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $587 |
| AstraZeneca | 21 | $359 |
| Merck | 11 | $201 |
| Novo Nordisk | 14 | $200 |
| Lilly USA, LLC | 7 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Axsome Therapeutics, Inc. | 5 | $87 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Amgen | 3 | $56 |
| Novartis | 3 | $51 |
| GSK | 3 | $47 |
| Boehringer Ingelheim | 3 | $44 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Pfizer | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Bayer | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,099 in reported general payments places this provider in the 70th percentile of 175 medical providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $63,627 |
| MounjaroTirzepatide | 46 | $57,451 |
| RybelsusSemaglutide | 48 | $49,361 |
| JardianceEmpagliflozin | 51 | $47,384 |
| OzempicSemaglutide | 47 | $45,838 |
| FarxigaDapagliflozin Propanediol | 47 | $40,788 |
| TrulicityDulaglutide | 22 | $25,398 |
| LinzessLinaclotide | 26 | $23,051 |
| JanuviaSitagliptin Phosphate | 32 | $21,586 |
| Repatha SureclickEvolocumab | 24 | $15,631 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,320 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $13,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,446 |
| MyrbetriqMirabegron | 15 | $10,375 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $9,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $200 | $95,19995 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $82,84968 claims |
| PfizerEliquis | $31 | $63,62794 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $44 | $57,17162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $359 | $51,23564 claims |
| AbbVieLinzess, Synthroid | $587 | $24,52548 claims |
| MerckJanuvia | $201 | $21,58632 claims |
| GSKTrelegy Ellipta | $47 | $15,32014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 medical providers in Alabama.
Other medical in Snead
- Lindsey MangumFlorence$44K
- Jaime DunnBirmingham$16K
- Stacy RichersonMobile$12K
- Susannah CashAuburn$11K
- Deana PorterAuburn$9K
- Rachel ThompsonFairhope$9K
- Shelley WinzelerHomewood$8K
- Reiga EvansHuntsville$8K
- Lillian ShafferCullman$8K
- Lauren TidwellHuntsville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.